Condition: Chidamide · R-CHOP Chemotherapy · DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: The First Affiliated Hospital with Nanjing Medical University
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
This description comes directly from the study's public registry record.
Wei Xu, Doctor · 86-2568302182 · xuwei10000@hotmail.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital with Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891157